Activating the Adipose Thermogenic Switch A First-in-Class Ucp1 saRNA Drives Durable, High-Quality Weight Loss in Diet-Induced Obese Mice（海报） 事件 Activating the Adipose Thermogenic Switch A First-in-Class Ucp1 saRNA Drives Durable, High-Quality Weight Loss in Diet-Induced Obese Mice（海报） 会议：American…RactigenJune 7, 2026
Safety, Biomarker Responses, and Preliminary Efficacy Following a Single Intrathecal Dose of RAG-17, a Novel siRNA Therapeutic for SOD1-ALS: Results from an Ongoing Phase I/II Study（海报） 事件 Safety, Biomarker Responses, and Preliminary Efficacy Following a Single Intrathecal Dose of RAG-17, a Novel siRNA Therapeutic for SOD1-ALS: Results from an Ongoing Phase I/II Study（海报） 会议：2026…RactigenApril 19, 2026
RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (摘要) 事件 RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial (摘要) 会议：American…ractigenApril 9, 2025
First-in-human study of RAG-01, a novel small activating RNA therapeutic in BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC) patients(摘要) RAG-01 Presentation事件 First-in-human study of RAG-01, a novel small activating RNA therapeutic in BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC) patients(摘要) 会议：40th…ractigenMarch 24, 2025
Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment (摘要) RAG-01 Presentation事件 Development and Clinical Progress of RAG-01, a Novel saRNA Targeting p21 for Non-Muscle Invasive Bladder Cancer Treatment (摘要) 会议:…ractigenOctober 11, 2024
RAG-17: A Promising Novel Gene Silencing Therapy for SOD1-ALS Preliminary Safety and Efficacy Data from a First-in-Human Trial (摘要) 事件 RAG-17: A Promising Novel Gene Silencing Therapy for SOD1-ALS Preliminary Safety and Efficacy Data from a First-in-Human Trial (摘要) 会议：Society…ractigenOctober 7, 2024
Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (海报) 事件 Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (海报) 会议：2024…ractigenMarch 21, 2024
SCAD: a platform technology for CNS delivery of duplex RNA by intrathecal administration (海报) 事件 SCAD: a platform technology for CNS delivery of duplex RNA by intrathecal administration (海报) 会议:…ractigenNovember 2, 2023
Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (海报) 事件 Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (海报) 会议:…ractigenNovember 2, 2023
Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (摘要) RAG-01 Presentation事件 Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. (摘要) 会议:…EnvisionJune 7, 2023
